Free Trial
  1. Trading of Rain Oncology was halted at 09:30 AM EST due to "LULD pause".
  2. This company has been marked as potentially delisted and may not be actively trading.

Rain Oncology (RAIN) Competitors

Rain Oncology logo

RAIN vs. ROSS, PRPB, HCMA, RANG, HCVI, BROG, BMAC, PLAO, SVII, and PLMJ

Should you be buying Rain Oncology stock or one of its competitors? The main competitors of Rain Oncology include Ross Acquisition Corp II (ROSS), CC Neuberger Principal Holdings II (PRPB), HCM Acquisition (HCMA), Range Capital Acquisition (RANG), Hennessy Capital Investment Corp. VI (HCVI), Brooge Energy (BROG), Black Mountain Acquisition (BMAC), Patria Latin American Opportunity Acquisition (PLAO), Spring Valley Acquisition Corp. II (SVII), and Plum Acquisition Corp. III (PLMJ).

Rain Oncology vs.

Ross Acquisition Corp II (NYSE:ROSS) and Rain Oncology (NASDAQ:RAIN) are both small-cap financial services companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Rain Oncology received 26 more outperform votes than Ross Acquisition Corp II when rated by MarketBeat users. Likewise, 52.00% of users gave Rain Oncology an outperform vote while only 0.00% of users gave Ross Acquisition Corp II an outperform vote.

CompanyUnderperformOutperform
Ross Acquisition Corp IIOutperform Votes
No Votes
Underperform Votes
1
100.00%
Rain OncologyOutperform Votes
26
52.00%
Underperform Votes
24
48.00%

Company Net Margins Return on Equity Return on Assets
Ross Acquisition Corp IIN/A N/A N/A
Rain Oncology N/A N/A -9.51%

Ross Acquisition Corp II has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Rain Oncology has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500.

In the previous week, Rain Oncology had 3 more articles in the media than Ross Acquisition Corp II. MarketBeat recorded 3 mentions for Rain Oncology and 0 mentions for Ross Acquisition Corp II. Ross Acquisition Corp II's average media sentiment score of 0.00 beat Rain Oncology's score of -0.29 indicating that Ross Acquisition Corp II is being referred to more favorably in the media.

Company Overall Sentiment
Ross Acquisition Corp II Neutral
Rain Oncology Neutral

27.8% of Ross Acquisition Corp II shares are held by institutional investors. Comparatively, 25.8% of Rain Oncology shares are held by institutional investors. 76.4% of Ross Acquisition Corp II shares are held by company insiders. Comparatively, 17.4% of Rain Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ross Acquisition Corp IIN/AN/A$14.87MN/AN/A
Rain OncologyN/AN/A$3.10MN/AN/A

Summary

Ross Acquisition Corp II beats Rain Oncology on 6 of the 9 factors compared between the two stocks.

Get Rain Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAIN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAIN vs. The Competition

MetricRain OncologyHolding Offices IndustryBusiness SectorNASDAQ Exchange
Market Cap$23.38M$480.21M$24.22B$8.31B
Dividend YieldN/A7.51%2.62%4.10%
P/E RatioN/A2.5332.5319.60
Price / SalesN/A74.06252.54117.96
Price / Cash7.4169.0130.9334.62
Price / Book-6.127.045.384.50
Net Income$3.10M$35.76M$195.96M$248.40M

Rain Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RAIN
Rain Oncology
N/A$4.22
-21.9%
N/AN/A$23.38MN/A0.0063Trading Halted
ROSS
Ross Acquisition Corp II
N/A$11.08
flat
N/AN/A$151.42MN/A0.003High Trading Volume
PRPB
CC Neuberger Principal Holdings II
N/A$1.80
+2.3%
N/A-52.8%$149.04MN/A0.004
HCMA
HCM Acquisition
N/A$10.46
-3.1%
N/A-4.9%$147.93MN/A0.00N/ANews Coverage
RANG
Range Capital Acquisition
N/A$10.13
-0.2%
N/AN/A$141.82MN/A0.00N/APositive News
Gap Up
HCVI
Hennessy Capital Investment Corp. VI
N/A$9.44
+2.0%
N/A-14.4%$138.17MN/A-8.823Gap Up
BROG
Brooge Energy
N/A$1.63
-4.1%
N/A+116.9%$137.34M$76.47M0.0023News Coverage
BMAC
Black Mountain Acquisition
N/A$10.60
flat
N/AN/A$125.54MN/A0.002,021High Trading Volume
PLAO
Patria Latin American Opportunity Acquisition
N/A$11.85
flat
N/AN/A$121.95MN/A0.00N/APositive News
SVII
Spring Valley Acquisition Corp. II
N/A$11.77
+0.8%
N/A+4.9%$116.24MN/A0.00N/A
PLMJ
Plum Acquisition Corp. III
N/A$11.08
-6.9%
N/A+2.5%$113.08MN/A0.002News Coverage
Gap Down

Related Companies and Tools


This page (NASDAQ:RAIN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners